Loading...
Loading...
CNTX| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 3.2K |
| Gross Profit | -3.2K |
| Operating Expense | 6,666.5K |
| Operating I/L | -6,666.5K |
| Other Income/Expense | 358.2K |
| Interest Income | 355.5K |
| Pretax | -6,308.3K |
| Income Tax Expense | -358.2K |
| Net Income/Loss | -5,950.1K |
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments for women in the United States. Their lead product candidate, onapristone extended release (ONA-XR), targets the progesterone receptor to overcome resistance to existing cancer therapies. Additionally, the company is working on CLDN6xCD3 bsAb, a bispecific monoclonal antibody designed to redirect T-cell-mediated lysis towards malignant cells expressing CLDN6. They generate revenue through the development and potential commercialization of these novel cancer therapeutics, as well as through collaboration and licensing agreements with partners in the biopharmaceutical industry.
